Advances of targeting CLDN18.2 in the treatment of gastric cancer
Claudin18.2(CLDN18.2),a member of the Claudin protein family,is one of the subtypes of CLDNs18.It is a highly tissue-specific protein that plays an important role in cellular tight junctions and is also involved in the proliferation,differentiation and migration of tumor cells.Recent studies have shown that Claudin18.2 is highly selective and stably expressed in gastric cancer and is therefore considered to be the most promising target for targeted gastric cancer therapy.Currently,antitumor therapy targeting CLDN18.2 has developed from single monoclonal antibody to bispecific antibody,including chimeric antigen receptor T cell therapy,and antibody drug conjugate with different regulatory mechanisms.In this article,the expression level of CLDN18.2 in gastric cancer,its clinical significance and its present therapeutic condition were briefly reviewed.
Gastric cancerClaudin18.2Chimeric antigen receptor T cellsAntibody-drug conjugatesOverview
NETL
NSTL
万方数据
